<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182583</url>
  </required_header>
  <id_info>
    <org_study_id>54.560</org_study_id>
    <nct_id>NCT02182583</nct_id>
  </id_info>
  <brief_title>Ba253BINEB Compared to Ba253MDI (Metered Dose Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Phase III Study of Ba253BINEB in Patients With COPD - Double-blind, Randomised, Double Dummy, Multiple Dose Study in Comparison With MDI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the efficacy and safety of Ba253BINEB during
      the continuous 4 weeks administration to the patients with COPD using Ba253MDI (Tersigan®
      aerosol) as the comparator drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 1998</start_date>
  <primary_completion_date type="Actual">June 2000</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in COPD daily symptom scores</measure>
    <time_frame>Baseline and up to 4 weeks after first drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in times of cough</measure>
    <time_frame>Baseline, up to 4 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in peak expiratory flow rate (PEFR)</measure>
    <time_frame>Baseline, up to 4 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Adverse Events</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with significant changes in vital sings (blood pressure, pulse rate)</measure>
    <time_frame>Baseline, week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in electrocardiogram (ECG)</measure>
    <time_frame>Baseline, week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in laboratory values</measure>
    <time_frame>Baseline, week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's global evaluation</measure>
    <time_frame>4 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's impression</measure>
    <time_frame>4 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in times and volume of sputum</measure>
    <time_frame>Baseline, up to 4 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in transition of nocturnal sleep</measure>
    <time_frame>Baseline, up to 4 weeks after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FEV1 (Forced expiratory volume in one second)</measure>
    <time_frame>Baseline, week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FVC (Forced vital capacity)</measure>
    <time_frame>Baseline, week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Ba253BINEB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ba253MDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ba253MDI</intervention_name>
    <arm_group_label>Ba253MDI</arm_group_label>
    <other_name>Tersigan® aerosol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ba253BINEB</intervention_name>
    <arm_group_label>Ba253BINEB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The patients with COPD (chronic bronchitis, emphysema) and who satisfy the following
        criteria

          1. Patients whose symptoms are stable and have at least 4 symptomatic days a week

          2. Patients with FEV1.0/FVC of &lt;= 70% in the screening test

          3. Patients aged &gt;= 40 years or older

          4. Patients must be able to inhale the study drug via BINEB and MDI

          5. Patients must be able to understand the patient information form

        Exclusion Criteria:

        Those who correspond to the following shall be excluded from the subjects of study.

          1. Patients complicated with bronchial asthma, making the assessment of drug efficacy
             against COPD difficult

          2. Patients who are constantly administered oral steroid

          3. Patients with glaucoma

          4. Patients who have prostatic hypertrophy

          5. Patients with hypersensitivity to anticholinergic drugs or Beta2 agonists.

          6. Patients with serious hepatic disease, kidney disease or heart disorder and who are
             judged by the investigator as inappropriate as the subjects of study

          7. Women who are pregnant or who may become pregnant, or nursing women

          8. Patients who are judged by the investigator as inappropriate as the subjects of the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 10, 2014</last_update_submitted>
  <last_update_submitted_qc>July 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxitropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

